MET and thyroid cancer: To our knowledge, this is the first report showing that acquired drug resistance to BRAF inhibition promotes not only tumor progression and proliferation, but also migration and invasion of BRAF (V600E) mutant thyroid cancer cells through upregulated EMT induced by c-Met-mediated AKT activation.